MINNEAPOLIS, June 14 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell Microcap® Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010.
"The preliminary addition of Uroplasty to the Russell Microcap Index could benefit our shareholders by increasing awareness of UPI among institutional investors, and the investment community in general, as we execute our strategies for our Urgent PC® and Macroplastique® product lines," said David Kaysen, President & CEO of Uroplasty.
The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market and is comprised of the smallest 1,000 companies in the Russell 3000® Index, plus the next smallest 1,000 companies. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The indexes are reconstituted annually.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB). We also offer Macroplastique Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that third-party payers will provide or continue to provide coverage and reimbursement for our products, or reimburse the providers an amount sufficient to cover their costs and expenses. We further cannot assure that reimbursement or other issues will not further impact our future results.
David Kaysen, President & CEO
Medi Jiwani, VP, CFO & Treasurer
EVC Group, Inc.
EVC Group, Inc.
SOURCE Uroplasty, Inc.